Microscope image of human cancer. Black dots on right side are lymphocytes being stopped by CAFs.
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug – originally developed to tackle the scarring of organ tissue – could help to significantly improve the success rate of cancer immunotherapy treatment.
Scientists have shown in mouse cancers, that GKT137831 (Setanaxib) can help break down the ‘barrier’ which makes many cancerous tumours resistant to immunotherapy drugs. GKT137831 is a drug currently undergoing clinical trials for treatment of organ fibrosis.
The team’s findings are published in the journal Cancer Research, a journal of the American Association for Cancer Research.
Immunotherapy treatment harnesses the power of the body’s own immune system to fight cancer. Its success depends on ‘killer’ lymphocytes penetrating into a tumour to combat malignant cells. However, most patients fail to respond, often because the lymphocytes are blocked at the edge of the tumour, preventing their attack. The scientists behind this latest study believe they have found why this happens and identified a way to overcome it – potentially improving immunotherapy treatment for many patients with different types of cancer.
The team found that normal cells called cancer-associated fibroblasts (CAF) are hijacked by cancer cells to protect them from immune attack. Fibroblasts are healthy cells that normally maintain the structure of tissues, but when they are corrupted by cancer cells, they become CAFs and shield tumours from lymphocyte attack and stop immunotherapy from working effectively. A significant proportion of many solid cancers are CAF-rich and associated with poor survival, including more than 50 percent of cases of head and neck, esophageal, colorectal and pancreatic cancers.
Previously, the group had identified that CAF formation depends on an enzyme called NOX4. In this study, they found that blocking NOX4 in mouse cancers, either genetically or with the drug GKT137831, could prevent and reverse CAF formation, allowing lymphocytes to infiltrate tumours and kill cancer cells*. Combining immunotherapies with GKT137831 was effective in treating tumours that were previously resistant, significantly improving survival**.
The findings could form the basis for making cancers respond better to existing immunotherapy drugs and demonstrate the potential for greatly improved clinical outcomes in a significant number of cancers. Cancer Research UK is currently funding the Southampton scientists to see if this approach improves immunotherapy in breast cancer.
Study author Professor Gareth Thomas, of the University of Southampton’s Centre for Cancer Immunology, comments: “Immunotherapy for cancer has been a very exciting development, but still doesn’t work in most patients. Our results suggest that in many cases, treatment resistance is caused by CAF, and we think this can be overcome by targeting NOX4. GKT137831 hasn’t yet been tested on cancer patients, but we hope may give immunotherapy drugs a much better chance of fighting cancer cells effectively; this technique could hugely improve the success rate of cancer immunotherapy.”
Liz Allaway, from Cancer Research UK says: “Immunotherapy is a promising cancer treatment that boosts the power of the body’s immune system against cancer, but unfortunately it doesn’t work for everyone. This exciting study showed that a drug, currently being tested for the treatment of another disease could make tumours in the lab more sensitive to immunotherapy. The next step would be to see if the drug has the same effect in people, which would open up immunotherapy as a treatment option for more people with cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cancer immunotherapy
- Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as ...
- Ketone supplement may boost immunotherapy against prostate cancer
Researchers have found that adding a pre-ketone supplement to immunotherapy boosted its effectiveness against prostate cancer in mouse models.
- Brain cancer in children is notoriously hard to treat—a new mRNA cancer vaccine triggers an attack from within
In 1991, scientists identified the first tumor antigen, helping lay the framework for modern-day immunotherapy. Since then, researchers have identified many new tumor antigens, facilitating the ...
- Oncolytic Virus to Be Studied in Advanced Lung Cancer
The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that progressed on standard therapy.
- Unlocking the immune system: cGAS-STING pathway offers new hope for cancer treatment
Cancer immunotherapy, which leverages the body's immune system to target tumors, has emerged as a pivotal strategy in oncology. This paradigm shift from conventional treatments offers a more precise ...
Go deeper with Google Headlines on:
Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Setanaxib
- Calliditas’ setanaxib to receive US patent entitled “Use of NOX Inhibitors for Treatment of Cancer”
The allowed claims cover a method of treating a solid tumour presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent, when ...
- Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
The allowed claims cover a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent ...
- Calliditas Gets Notice Of Allowance For U.S. Patent Application Covering Setanaxib To Treat Cancer
The allowed claims cover a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent ...
Go deeper with Google Headlines on:
Setanaxib
[google_news title=”” keyword=”Setanaxib” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]